DPP-4 inhibitors and COVID-19 outcomes

The French CORONADO study provides reassuring data about the safety of dipeptidyl peptidase-4 inhibitors in the context of the pandemic, and suggests that prescribing practice need not be changed.

Click here to read our summary.

Share this article

EMPEROR-Preserved: Positive results for empagliflozin in people with HFpEF announced

Diabetes before, during and after pregnancy

Early-onset and youth-onset type 2 diabetes: new factsheet

Ramadan and the management of diabetes

Diagnosing and treating hypertension in type 2 diabetes

DPP-4 inhibitors and COVID-19 outcomes

Diabetic Charcot arthropathy: new factsheet

EMPEROR-Preserved: Positive results for empagliflozin in people with HFpEF announced

Results of the EMPEROR-Preserved trial suggest that empagliflozin significantly improves outcomes in adults with HFpEF, regardless of diabetes status.

12 Jul 2021

Diabetes before, during and after pregnancy

Diabetes is the most common medical complication of pregnancy and its incidence is increasingly.

14 Jun 2021

Early-onset and youth-onset type 2 diabetes: new factsheet

As part of its “At a Glance” series, Diabetes & Primary Care has published a factsheet on early-onset type 2 diabetes and its subset, youth-onset type 2 diabetes, which affects children and adolescents. The personal and public health implications of developing type 2 diabetes early in life are significant. While its prevalence in people under the age of 45 is still relatively low, it is steadily increasing.

2 Jun 2021

For the latest news and articles

Resources

Journals

Useful information